Intermittent administration of PTH for the treatment of inflammatory bone loss does not enhance entheseal pathological new bone formation
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2024.149888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Shuai Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spine Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong, China; Guangdong Province Key Labor…. Hauptthemen laut MEDLINE: Parathyroid Hormone, Osteogenesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVE: To investigate the effect of intermittent parathyroid hormone (iPTH) administration on pathological new bone formation during treatment of ankylosing spondylitis-related osteoporosis. METHODS: Animal models with pathological bone formation caused by hypothetical AS pathogenesis received treatment with iPTH. We determined the effects of iPTH on bone loss and the formation of pathological new bone with micro-computed tomography (micro-CT) and histological examination. In addition, the tamoxifen-inducible conditional knockout mice (CAGGCre-ERTM; PTHflox/flox, PTH-/-) was established to delete PTH and investigate the effect of endogenous PTH on pathological new bone formation. RESULTS: iPTH treatment significantly improved trabecular bone mass in the modified collagen-induced arthritis (m-CIA) model and unbalanced mechanical loading models. Meanwhile, iPTH treatment did not enhance pathological new bone formation in all types of animal models. Endogenous PTH deficiency had no effects on pathological new bone formation in unbalanced mechanical loading models. CONCLUSION: Experimental animal models of AS treated with iPTH show improvement in trabecular bone density, but not entheseal pathological bone formation,indicating it may be a potential treatment for inflammatory bone loss does in AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Spine Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong, China; Guangdong Province Key Laboratory of Orthopaedics and Traumatology, Guangzhou, 510080, Guangdong,…
- Department of Rheumatology and Immunology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, Guangdong, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, S., Hao, W., Chen, D., Chen, S., Li, Z., Zhong, F., Wang, H., Wang, J., Zheng, Z., Zhan, Z., Dai, G., & Liu, H. (2024). Intermittent administration of PTH for the treatment of inflammatory bone loss does not enhance entheseal pathological new bone formation. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.149888
Vancouver
Zhang S, Hao W, Chen D, Chen S, Li Z, Zhong F, et al. Intermittent administration of PTH for the treatment of inflammatory bone loss does not enhance entheseal pathological new bone formation. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.149888
BibTeX
@article{Zhang2024,
author = {Zhang, Shuai and Hao, Wenjun and Chen, Dongying and Chen, Siwen and Li, Zihao and Zhong, Fangling and Wang, Haitao and Wang, Jianru and Zheng, Zhaomin and Zhan, Zhongping and Dai, Guo and Liu, Hui},
title = {Intermittent administration of PTH for the treatment of inflammatory bone loss does not enhance entheseal pathological new bone formation},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2024.149888}
}
EUVIMED